Ege David S.'s Form 4 filing
Seres Therapeutics, Inc. (MCRB) · filed Oct 31, 2022
- Accession no.
- 0000899243-22-034598
- Filed
- Oct 31, 2022
- Trade date
- Oct 27-31, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $39.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ege David S.CIK 0001829360 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 27, 2022 | Common stock | AGrant or awardAcquired | +20,000 | $0.00 | $0 | 51,746 | Direct | |
| Oct 31, 2022 | Common stock | SSaleDisposed | −5,012 | $7.93 | −$39,745.16 | 46,734 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Executive Vice President and Chief Technology Officer